Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ROVIDIUM is a dietary supplement product series developed by SanuLife, designed to address both aging and cancer. The name is an acronym for 'RhoB inducer' (RO for RhoB tumor suppressor gene, VI for revival, and DIUM for matrix). It is a small molecule formulation containing high-purity active ingredients, including rice germ and rice bran extract (Ceramide), turmeric extract (Curcumin), and green tea extract (epigallocatechin gallate, or EGCG). The product works by harnessing the tumor suppressor gene RhoB and endogenous longevity transcriptional factors to protect normal cells while targeting cancer cells. ROVIDIUM is produced in California according to cGMP standards and was launched in the United States in August 2018. The ingredients are classified by the US FDA as 'Generally Recognized as Safe' (GRAS). It is available in both core and luxury versions, with the luxury version containing additional components such as Coenzyme Q10 (CoQ10), Pyrroloquinoline quinone (PQQ), and B vitamins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rovidium.